Search

Insulet Corp

Open

SectorHealthcare

167.09 1.33

Overview

Share price change

24h

Current

Min

164.31

Max

172.83

Key metrics

By Trading Economics

Income

-11M

91M

Sales

-22M

762M

P/E

Sector Avg

38.3

62.58

EPS

1.42

Profit margin

11.96

Employees

5,400

EBITDA

-23M

154M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+34.17% upside

Dividends

By Acuity

Next Earnings

5 sie 2026

Market Stats

By TradingEconomics

Market Cap

-278M

12B

Previous open

165.76

Previous close

167.09

News Sentiment

By Acuity

63%

37%

295 / 340 Ranking in Healthcare

Insulet Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

27 lip 2026, 20:06 UTC

Insulet Corp shares are higher today, reflecting broader market trends despite an earlier pullback from a session high. No specific news was identified.

24 lip 2026, 22:26 UTC

Insulet Corp shares are lower in after-market hours, following a decline from earlier session lows. No specific company news was identified to explain the movement.

22 lip 2026, 20:01 UTC

News

Insulet Corp shares are lower amid a class action lawsuit alleging securities fraud related to safety claims about its Omnipod products.

20 lip 2026, 18:36 UTC

News

Insulet Corp is gaining today after being identified as a healthcare stock likely to deliver sustainable market-beating returns, despite ongoing legal challenges.

Peer Comparison

Price change

Insulet Corp Forecast

Price Target

By TipRanks

34.17% upside

12 Months Forecast

Average 221.38 USD  34.17%

High 294 USD

Low 172 USD

Based on 22 Wall Street analysts offering 12 month price targets forInsulet Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

22 ratings

18

Buy

3

Hold

1

Sell

Sentiment

By Acuity

295 / 340 Ranking in Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Insulet Corp

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
help-icon Live chat